Skip to main content
Samuel Funt, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

SamuelAFuntMD

Oncology New York, NY

Genitourinary Oncology, Hematologic Oncology

Medical Oncology Fellow

Overview of Dr. Funt

Dr. Samuel Funt is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Emory University School of Public Health and has been in practice 7 years. He is one of 389 doctors at Memorial Sloan-Kettering Cancer Center who specialize in Oncology.

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFellowship, Medical Oncology, 2014
  • New York Presbyterian Hospital -  Columbia Campus
    New York Presbyterian Hospital - Columbia CampusChief Residency, Internal Medicine, 2013 - 2014
  • New York Presbyterian Hospital -  Columbia Campus
    New York Presbyterian Hospital - Columbia CampusResidency, Internal Medicine, 2010 - 2013
  • Emory University School of Public Health
    Emory University School of Public HealthClass of 2010

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2021 - Present
  • NJ State Medical License
    NJ State Medical License 2019 - 2023
  • NY State Medical License
    NY State Medical License 2011 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2013-2016

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Presence of Teratoma and Disease-Related Death in Advanced Germ Cell Tumors
    Presence of Teratoma and Disease-Related Death in Advanced Germ Cell TumorsJuly 1st, 2019
  • A Pipeline to a Medical Career
    A Pipeline to a Medical CareerAugust 20th, 2021
  • Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt
    Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. FuntJuly 30th, 2021

Hospital Affiliations